| Feb. 1, 2010 |
Summa Health System, Kent State University and University of Akron of Ohio renew Sponsored Research Agreements. Research enters fourth year investigating new drugs and drug delivery systems. |
| Jan. 6, 2010 |
Conceived and organized by Dr. Jacques Gilloteaux, IC-MedTech and Summa Health Systems are Sponsoring the 1st International Symposium for INNOVATIVE ANTICANCER DRUGS AND STRATEGIES to be held June 2-4, 2010 at Northumbria University with St Georges’ University School of Medicine, KBT Global Scholars’ Programme, Newcastle upon Tyne, UK. Link to the pdf |
|
| Nov. 11, 2009 |
Aseptic Osteolysis clinical study protocol filed for human patient safety review |
| Sept. 25, 2009 |
Summa holds first annual Research Forum – Forum features several papers and presentations on Apatone and Tolecine Link to the pdf |
| Aug. 31, 2009 |
Summa Health System establishes Apatone Development Center at St. Thomas Hospital |
| July 20, 2009 |
Summa and IC-MedTech file patent application for Apatone in treatment of osteolysis |
| June 2009 |
Tolecine fails to show efficacy in vivo |
| Feb. 2009 |
IC-MedTech hires CRO’s Charles River, Huntingdon Life Science and Southern Research |
|
| Oct. 23, 2008 |
Researchers report promising results for bioactivity of Tolecine in melanoma |
| Mar. 31, 2008 |
A 12 Week, Open Label, Phase I/IIa Study Using Apatone® for the Treatment of Prostate Cancer Patients Who Have Failed Standard Therapy. Link to the Study |
|
| Sept. 6, 2007 |
Kent State University introduces Liquid Crystal Pharmaceuticals™ as a "New Drug Paradigm" |
| Aug. 2, 2007 |
Billings Clinic Cancer Center selected as next clinical study site. |
| July 31, 2007 |
FDA approves Apatone for For The Treatment Of Metastatic Or Locally Advanced, Inoperable Transitional Cell Carcinoma Of The Urothelium (stage III and IV urinary bladder cancer) |
| June 2007 |
Kent State University and Summa Health System Agree To Continuing Joint Apatone Research Project. IC-MedTech files for new patents and trademark for Anniahlase™ |
| Apr. 2007 |
IC-MedTech licenses two patents from Kent State, files for Tolecine™ mark. |
| Mar. 2007 |
IC-MedTech and Kent State University agree to LCP research collaboration. |
| Jan. 2007 |
IC-MedTech files for LCP™ trademark - new drug development platform. |
|
| Oct. 2006 |
Journal of Urology- October 2006: Vitamins C and K3 (Apatone®) sensitize human urothelial tumors to gemcitabine. Read More |
| Sept. 14, 2006 |
Preliminary results - Pilot Study using Apatone® for the Study of Prostate Cancer Patients presented to the American Urological Association. Read More |
| Aug. 15, 2006 |
Apatone® patent issues. |
| Mar. 9, 2006 |
IC-MedTech, Kent State University and Summa Health System Agree To Joint Research Project. Read More |
| Mar. 2006 |
Clinical Research Management reports positive biostatistics from second human study. |
| Mar. 2006 |
IC-MedTech, Kent State University and Summa Health System agree to research collaboration. |
| Feb. 2006 |
IC-MedTech partners with CRO, Clinical Research Management for regulatory oversight of clinical trials program. |
| Jan. 2006 |
IC-MedTech converts to "C" corporation from LLC
"Morphology and DNA Degeneration During Autoschizic Cell Death in Bladder Carcinoma T24 Cells Induced by Ascorbate and Menadione Treatment" published in centennial issue of Anatomical Record. |
|
| Dec. 2005 |
U.S. Patent and Trademark Office awards claims. Patent pending. |
| Sept. 2005 |
IC-MedTech secures private funding for Apatone® drug development platform. |
| June 2005 |
"Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study" published in Free Radical Research. |
| Apr. 25, 2005 |
Nova Science publishes chapter on IC-MedTech's drug treatment research in "Trends in Prostate Cancer Research" by John Lucas. Read More |
| Jan. 4, 2005 |
Phase I/II prostate cancer pilot clinical trial begins. |
